41 BrainSee is the name of a Software platform which has recently received FDA approval for its use by doctors and clinicians to evaluate patients with mild cognitive impairment and to identify patient risk of progression to Alzheimer's dementia within 5 years. BrainSee has 3 core underlying technological modules, each of which can be called BrainSee software element: 1) brain image analysis module, 2) AI module, and 3) fully automated, HIPAA-compliant, FDA approved Cybersecurity platform
Trademark: 98486085
